Wall Street brokerages expect that Acorda Therapeutics Inc (NASDAQ:ACOR) will post earnings per share of $0.01 for the current fiscal quarter, Zacks reports. Seven analysts have provided estimates for Acorda Therapeutics’ earnings. The highest EPS estimate is $0.25 and the lowest is ($0.34). Acorda Therapeutics reported earnings per share of $0.43 in the same quarter last year, which suggests a negative year over year growth rate of 97.7%. The business is expected to issue its next quarterly earnings results on Tuesday, October 30th.

On average, analysts expect that Acorda Therapeutics will report full-year earnings of $0.48 per share for the current year, with EPS estimates ranging from ($0.05) to $1.13. For the next year, analysts forecast that the company will report earnings of ($3.76) per share, with EPS estimates ranging from ($4.35) to ($2.74). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Acorda Therapeutics.

Acorda Therapeutics (NASDAQ:ACOR) last released its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $0.50 by $0.90. Acorda Therapeutics had a negative net margin of 26.87% and a positive return on equity of 8.19%. The firm had revenue of $153.30 million during the quarter, compared to analysts’ expectations of $138.63 million. During the same period in the previous year, the company earned $0.29 EPS. The firm’s revenue for the quarter was up 10.0% compared to the same quarter last year.

ACOR has been the subject of a number of recent analyst reports. BidaskClub cut shares of Acorda Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 19th. TheStreet raised shares of Acorda Therapeutics from a “d+” rating to a “c-” rating in a research note on Tuesday, June 19th. Zacks Investment Research raised shares of Acorda Therapeutics from a “hold” rating to a “buy” rating and set a $33.00 price target for the company in a research note on Tuesday, July 3rd. ValuEngine cut shares of Acorda Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 18th. Finally, JPMorgan Chase & Co. reissued a “hold” rating on shares of Acorda Therapeutics in a research report on Wednesday, July 25th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $24.17.

Shares of ACOR stock traded up $0.13 during trading hours on Monday, reaching $17.68. 587,654 shares of the stock were exchanged, compared to its average volume of 651,743. Acorda Therapeutics has a 12-month low of $15.60 and a 12-month high of $36.35. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.56. The stock has a market cap of $933.06 million, a PE ratio of 17.00 and a beta of 1.52.

In other news, major shareholder Scopia Capital Management Lp sold 13,829 shares of the company’s stock in a transaction that occurred on Thursday, September 6th. The shares were sold at an average price of $27.82, for a total value of $384,722.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Burkhard Blank sold 6,250 shares of the company’s stock in a transaction that occurred on Wednesday, August 1st. The stock was sold at an average price of $24.69, for a total transaction of $154,312.50. Following the completion of the sale, the insider now directly owns 34,400 shares of the company’s stock, valued at approximately $849,336. The disclosure for this sale can be found here. Insiders sold a total of 750,672 shares of company stock valued at $16,623,449 in the last ninety days. Corporate insiders own 7.80% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in ACOR. Aperio Group LLC lifted its position in shares of Acorda Therapeutics by 18.1% in the 1st quarter. Aperio Group LLC now owns 15,709 shares of the biopharmaceutical company’s stock worth $372,000 after purchasing an additional 2,403 shares during the period. Northern Trust Corp lifted its position in shares of Acorda Therapeutics by 0.5% in the 1st quarter. Northern Trust Corp now owns 1,042,123 shares of the biopharmaceutical company’s stock worth $24,647,000 after purchasing an additional 5,140 shares during the period. California Public Employees Retirement System lifted its position in shares of Acorda Therapeutics by 10.1% in the 1st quarter. California Public Employees Retirement System now owns 75,364 shares of the biopharmaceutical company’s stock worth $1,782,000 after purchasing an additional 6,912 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Acorda Therapeutics by 5.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 3,121,775 shares of the biopharmaceutical company’s stock worth $73,830,000 after purchasing an additional 167,084 shares during the period. Finally, Principal Financial Group Inc. lifted its position in shares of Acorda Therapeutics by 2.9% in the 1st quarter. Principal Financial Group Inc. now owns 367,973 shares of the biopharmaceutical company’s stock worth $8,703,000 after purchasing an additional 10,536 shares during the period.

About Acorda Therapeutics

Acorda Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.

Featured Article: Growth Stocks

Get a free copy of the Zacks research report on Acorda Therapeutics (ACOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.